Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

"We have about eight patients that are in the insurance approval process," she said, for gene therapy treatments for beta thalassemia and sickle cell disease. "It's something that we do expect to ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Detroit — The Detroit Medical Center has begun treating patients with the first gene therapy for beta-thalassemia, a rare blood disorder that causes anemia and often requires regular blood ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Amwins Group Benefits is now expanding its Gene Therapy Solutions (GTS) program to 15 gene and cell therapies, up from the ...